Skandinaviska Enskilda Banken AB publ Has $260.47 Million Position in Eli Lilly and Company (NYSE:LLY)

Skandinaviska Enskilda Banken AB publ increased its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 1.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 336,599 shares of the company's stock after acquiring an additional 4,722 shares during the period. Eli Lilly and Company makes up 1.2% of Skandinaviska Enskilda Banken AB publ's portfolio, making the stock its 14th biggest position. Skandinaviska Enskilda Banken AB publ's holdings in Eli Lilly and Company were worth $260,474,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of LLY. Principal Financial Group Inc. grew its position in Eli Lilly and Company by 5.3% in the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company's stock valued at $1,070,698,000 after buying an additional 60,306 shares in the last quarter. GSA Capital Partners LLP bought a new position in Eli Lilly and Company in the 3rd quarter valued at about $606,000. Carrera Capital Advisors bought a new position in Eli Lilly and Company in the 3rd quarter valued at about $244,000. Moser Wealth Advisors LLC grew its position in Eli Lilly and Company by 40.0% in the 3rd quarter. Moser Wealth Advisors LLC now owns 455 shares of the company's stock valued at $403,000 after buying an additional 130 shares in the last quarter. Finally, Empower Advisory Group LLC grew its position in Eli Lilly and Company by 4.3% in the 3rd quarter. Empower Advisory Group LLC now owns 139,274 shares of the company's stock valued at $123,388,000 after buying an additional 5,682 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on LLY shares. Wolfe Research started coverage on shares of Eli Lilly and Company in a research report on Friday, November 15th. They issued an "outperform" rating and a $1,000.00 target price for the company. Morgan Stanley set a $1,146.00 target price on shares of Eli Lilly and Company in a research report on Thursday, March 6th. Berenberg Bank set a $970.00 target price on shares of Eli Lilly and Company in a research report on Thursday, January 16th. Truist Financial raised their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research report on Monday, February 3rd. Finally, Citigroup reduced their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research report on Tuesday, January 28th. Three research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and an average target price of $1,009.72.

Eli Lilly and Company Stock Down 2.9 %

Shares of NYSE LLY traded down $23.47 during mid-day trading on Thursday, reaching $798.39. The company had a trading volume of 3,564,332 shares, compared to its average volume of 3,129,621. The stock has a fifty day moving average of $830.18 and a two-hundred day moving average of $844.96. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The company has a market capitalization of $757.01 billion, a price-to-earnings ratio of 68.18, a PEG ratio of 1.40 and a beta of 0.34. Eli Lilly and Company has a 12-month low of $711.40 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company announced that its Board of Directors has initiated a stock repurchase program on Monday, December 9th that authorizes the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy up to 2% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's management believes its stock is undervalued.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 0.13% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.